The California Healthcare Institute (CHI) will host Keeping Pace with Technology: Molecular Diagnostics Regulation and Reimbursement, Wednesday, Sept. 17, 10:00 a.m. to 6:00 p.m. at Gen-Probe Incorporated in San Diego – located at 10210 Genetic Center Drive, San Diego, Calif. 92121. This forum will feature many national experts in molecular diagnostics technology, reimbursement and regulation industry including: Mari Baker, president and chief executive officer, Navigenics, Inc.; Jeff Bush, director of corporate reimbursement, BD; Robert DiTullio, vice president of regulatory affairs and quality, ProteoGenix, Inc.; Alberto Gutierrez, Ph.D., deputy director, Office of In Vitro Diagnostic Device (OIVD) Safety and Evaluation, Center for Devices and Radiological Health (CDRH), FDA; Sheri Hall, vice president of regulatory affairs and quality, BD; Richard Jove, Ph.D.; director, Beckman Research Institute, City of Hope; Hank Nordhoff, chairman and CEO, Gen-Probe Incorporated; Hakan Sakul, Ph.D.; senior director and global head of diagnostics, Pfizer Global Research and Development; Patrick Terry, co-founder and director, Consumer Advocacy and Governmental Affairs, Genomic Health; and Tim Wolleager, managing director, Sanderling Ventures.
This panel of experts will discuss how the IVD industry has evolved and expanded our knowledge of the molecular base of cancer and other chronic diseases, and how the federal and state government regulatory and reimbursement agencies are slowing down progress. A few topics that will be covered are Emerging Regulatory Trends; A 21 Century Payment Framework; and Diagnostics, Personalized Medicine and Key Issues in Healthcare Reform.
Technology is constantly changing and advancing our knowledge of genetics, said David Gollaher, Ph.D., president and CEO, CHI “ California Healthcare Institute. We need to rethink and rework federal and state policies to help accelerate technology not slow it down.
Keeping Pace with Technology: Molecular Diagnostics Regulation and Reimbursement is sponsored by Gen-Probe Incorporated, BD and Roche and hosted by David Gollaher, Ph.D., president and CEO, CHI.
Registration for this event is $50 for CHI members and $100 for non-members; to register for this event, please call (858) 551-6677. CHI represents more than 250 leading biotechnology, diagnostics, medical device and pharmaceutical companies and public and private academic biomedical research organizations. CHI™s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI™s Web site is www.chi.org.
California Healthcare Institute
Tiffany Taluban, 858-551-6677
taluban@chi.org